Novel drug delivery systems in topical treatment of psoriasis: Rigors and vigors

Indian Journal of Dermatology, Venereology and Leprology

Volumn 76, Issue 6, 2010, Pages 612-621

  Katare, Om ^a   Raza, Kaisar ^a   Singh, Bhupinder ^a   Dogra, Sunil ^b  

^a PANJAB UNIVERSITY   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Dermal drug delivery; Liposomes; Microemulsions; Nanoparticles; Phospholipids; Vesicles

Indexed keywords

22 OXACALCITRIOL; AMINOLEVULINIC ACID; BERGAPTEN; BETAMETHASONE DIPROPIONATE; CALCIPOTRIOL; CALCITRIOL; CHITOSAN; COAL TAR; CYCLOSPORIN A; DENDRIMER; DIPROPHYLLINE; DITHRANOL; DRUG CARRIER; GLYCEROL OLEATE; LIPID EMULSION; LIPOSOME; METHOTREXATE; METHOXSALEN; NIOSOME; PHOSPHOLIPID; PROPYLENE GLYCOL; RETINOIC ACID; SOLID LIPID NANOPARTICLE; TACALCITOL; TACROLIMUS; TAMOXIFEN; TEMOPORFIN; TRIOXYSALEN; TRIPTOLIDE; UNINDEXED DRUG;

BIOCOMPATIBILITY; BIODEGRADABILITY; CLINICAL TRIAL; CONFERENCE PAPER; CREAM; DRUG DELIVERY SYSTEM; DRUG MIXTURE; DRUG PENETRATION; ECZEMA; HUMAN; HYDROGEL; MICROEMULSION; NANOEMULSION; NONHUMAN; PERMEABILITY BARRIER; PSORIASIS; PSORIASIS VULGARIS; SKIN; SKIN BURNING SENSATION; SKIN MANIFESTATION; SKIN SCALING; SKIN STINGING;

ADMINISTRATION, TOPICAL; ANIMALS; DERMATOLOGIC AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; PSORIASIS;

EID: 78649309082     PISSN: 03786323     EISSN: 09733922     Source Type: Journal    
DOI: 10.4103/0378-6323.72451     Document Type: Conference Paper

References (124)

1. Finlay AY, Ortonne J P. Patient satisfaction with psoriasis therapies: An update and introduction to biologic therapy. J Cutan Med Surg 2004;8:310-20.
2. Fouere S, Adjadj L, Pawin H. How patients experience psoriasis: Results from a European survey. J Eur Acad Dermatol Venereol 2005;19:2-6.
3. Bos JD, Spuls PI. Topical treatments in psoriasis: Today and tomorrow. Clin Dermatol 2008;26:432-37.
4. Morganti P, Ruocco E, Wolf R, Ruocco V. Percutaneous absorption and delivery systems. Clin Dermatol 2001;19:489-501.
5. Hadgraft J. Recent developments in topical and transdermal delivery. Eur J Drug Metab Pharmacokinet 1996;21:165-73.
6. Wertz PW, Madison KC, Downing DT. Covalently bound lipids of human stratum corneum. J Invest Dermatol 1989;92:109-11.
7. de Leeuw J, de Vijlder HC, Bjerring P, Neumann HA. Liposomes in dermatology today. J Eur Acad Dermatol Venereol 2009;23:505-16.
8. Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: An update review. Curr Drug Deliv 2007;4:297-305.
9. Goyal P, Goyal K, Vijaya Kumar SG, Singh A, Katare O P, Mishra DN. Liposomal drug delivery systems-clinical applications. Acta Pharm 2005;55:1-25.
10. Talegaonkar S, Azeem A, Ahmad FJ, Khar RK, Pathan SA, Khan ZI. Microemulsions: A novel approach to enhanced drug delivery. Recent Pat Drug Deliv Formul 2008;2:238-57.
11. Bali V, Bhavna, Ali M, Baboota S, Ali J. Potential of microemulsions in drug delivery and therapeutics: A patent review. Recent Pat Drug Deliv Formul 2008;2:136-44.
12. Azmin MN, Florence AT, Handjani-Vila RM, Stuart J F, Vanlerberghe G, Whittaker JS. The effect of non-ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice. J Pharm Pharmacol 1985;37:237-42.
13. Rogerson A, Cummings J, Willmott N, Florence AT. The distribution of doxorubicin in mice following administration in niosomes. J Pharm Pharmacol 1988;40:337-42.
14. Baillie AJ, Coombs GH, Dolan T F, Laurie J. Non-ionic surfactant vesicles, niosomes, as a delivery system for the anti-leishmanial drug, sodium stibogluconate. J Pharm Pharmacol 1986;38:502-5.
15. Singh B, Kapil R, Bandopadhyay S, Katare O P. Dendrimers as nanobiopolymers: Drug delivery applications. Pharma Buzz 2009;34-43.
16. Dragicevic-Curic N, Scheglmann D, Albrecht V, Fahr A. Temoporfin-loaded invasomes: Development, characterization and in vitro skin penetration studies. J Control Release 2008;127:59-69.
17. Dragicevic-Curic N, Scheglmann D, Albrecht V, Fahr A. Development of different temoporfin-loaded invasomes-novel nanocarriers of temoporfin: Characterization, stability and in vitro skin penetration studies. Colloids Surf B Biointerfaces 2009;70:198-206.
18. zur Muhlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm 1998;45:149-55. (Pubitemid 28167741)
19. Freitas C, Muller RH. Stability determination of solid lipid nanoparticles (SLN) in aqueous dispersion after addition of electrolyte. J Microencapsul 1999;16:59-71.
20. Pardeike J, Hommoss A, Muller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2009;366:170-84.
21. Souto EB, Muller RH. Cosmetic features and applications of lipid nanoparticles (SLN, NLC). Int J Cosmet Sci 2008;30:157-65.
22. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - A review of the state of the art. Eur J Pharm Biopharm 2000;50:161-77.
23. Muller RH, Petersen RD, Hommoss A, Pardeike J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev 2007;59:522-30.
24. Singh B, Bandopadhyay S, Kapil R, Katare O P. Nanostructured lipid carriers as novel drug delivery vehicles. Pharma Buzz 2008;38-46.
25. Kim ST, Jang DJ, Kim JH, Park JY, Lim JS, Lee S Y, et al. Topical administration of cyclosporin A in a solid lipid nanoparticle formulation. Pharmazie 2009;64:510-14.
26. Tran C, Lubbe J, Sorg O, Doelker L, Carraux P, Antille C, et al. Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis. Dermatology 2005;211:341-47.
27. Hamada Y, Komatsu T, Seto Y, Matsubara H, Kume H, Sunakawa K, et al. Liposomal-amphotericin B efficacy and safety. Kansenshogaku 2010;84:193-8.
28. Gupta M, Goyal AK, Paliwal SR, Paliwal R, Mishra N, Vaidya B, et al. Development and characterization of effective topical liposomal system for localized treatment of cutaneous candidiasis. J Liposome Res 2010 [In Press].
29. Bhalaria MK, Naik S, Misra AN. Ethosomes: A novel delivery system for antifungal drugs in the treatment of topical fungal diseases. Indian J Exp Biol 2009;47:368-75.
30. Pannu J, McCarthy A, Martin A, Hamouda T, Ciotti S, Fothergill A, et al. NB-002, a novel nanoemulsion with broad antifungal activity against dermatophytes, other filamentous fungi, and Candida albicans. Antimicrob Agents Chemother 2009;53:3273-39.
31. Patel R P, Patel H, Baria AH. Formulation and Evaluation of Liposomes of Ketoconazole. Int J Drug Deliv Technol 2009;1:42-45.
32. Verma AM, Palani S. Development and in-vitro evaluation of liposomal gel of ciclopirox olamine. Int J Pharm Bio Sci 2010;1.
33. Trotta M, Peira E, Carlotti ME, Gallarate M. Deformable liposomes for dermal administration of methotrexate. Int J Pharm 2004;270:119-25.
34. Dubey V, Mishra D, Dutta T, Nahar M, Saraf DK, Jain NK. Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. J Control Release 2007;123:148-54.
35. Lakshmi PK, Devi GS, Bhaskaran S, Sacchidanand S. Niosomal methotrexate gel in the treatment of localized psoriasis: Phase I and phase II studies. Indian J Dermatol Venereol Leprol 2007;73:157-61.
36. Ali M F, Salah M, Rafea M, Saleh N. Liposomal methotrexate hydrogel for treatment of localized psoriasis: Preparation, characterization and laser targeting. Med Sci Monit 2008;14: PI66-74.
37. Dragicevic-Curic N, Winter S, Krajisnik D, Stupar M, Milic J, Graefe S, et al. Stability evaluation of temoporfin-loaded liposomal gels for topical application. J Liposome Res 2010;20:38-48.
38. Agarwal R, Katare O P, Vyas S P. Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharm 2001;228:43-52.
39. Saraswat A, Agarwal R, Kaur I, Katare O P, Kumar B. Fabricstaining properties and washability of a novel liposomal dithranol formulation. J Dermatolog Treat 2002;13:119-22.
40. Saraswat A, Agarwal R, Katare O P, Kaur I, Kumar B. A randomized, double-blind, vehicle-controlled study of a novel liposomal dithranol formulation in psoriasis. J Dermatolog Treat 2007;18:40-5.
41. Agarwal R, Saraswat A, Kaur I, Katare O P, Kumar B. A novel liposomal formulation of dithranol for psoriasis: Preliminary results. J Dermatol 2002;29:529-32.
42. Bhatia A, Mangat P, Jain B, Singh B, Katare O P. Washability and fabric-staining properties of a novel phospholipid-structured coal tar formulation. J Dermatolog Treat 2008;19:105-10.
43. Fernandez JM, Knudson MB. Method of delivering a lipidcoated condensed-phase microparticle composition. United States: United States Patent Office; 1995.
44. Jenkins S, Liversidge G, Liversidge E. Nanoparticulate tacrolimus formulations. United States: United States Patent Office; 2008.
45. Erdogan M, Wright JR, McAlister VC. Liposomal tacrolimus lotion as a novel topical agent for treatment of immunemediated skin disorders: experimental studies in a murine model. Br J Dermatol 2002;146:964-7.
46. Elzainy AA, Gu X, Simons FE, Simons KJ. Cetirizine from topical phosphatidylcholine-hydrogenated liposomes: Evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. AAPS J 2004;6: e18.
47. Lim GJ, Ishiuji Y, Dawn A, Harrison B, Kim do W, Atala A, et al. In vitro and in vivo characterization of a novel liposomal butorphanol formulation for treatment of pruritus. Acta Derm Venereol 2008;88:327-30.
48. Yang D, Pornpattananangkul D, Nakatsuji T, Chan M, Carson D, Huang CM, et al. The antimicrobial activity of liposomal lauric acids against Propionibacterium acnes. Biomaterials 2009;30:6035-40.
49. Esposito E, Menegatti E, Cortesi R. Ethosomes and liposomes as topical vehicles for azelaic acid: A preformulation study. J Cosmet Sci 2004;55:253-64.
50. Patel VB, Misra A, Marfatia YS. Topical liposomal gel of tretinoin for the treatment of acne: Research and clinical implications. Pharm Dev Technol 2000;5:455-64.
51. Patel VB, Misra AN, Marfatia YS. Preparation and comparative clinical evaluation of liposomal gel of benzoyl peroxide for acne. Drug Dev Ind Pharm 2001;27:863-9.
52. Seth AK, Misra A, Umrigar D. Topical liposomal gel of idoxuridine for the treatment of herpes simplex: Pharmaceutical and clinical implications. Pharm Dev Technol 2004;9:277-89.
53. Trotta M, Peira E, Debernardi F, Gallarate M. Elastic liposomes for skin delivery of dipotassium glycyrrhizinate. Int J Pharm 2002;241:319-27.
54. Ismailova GK, Efremenko VI, Savel'eva I V, logvinenko OV. Efficacy of a new magnet-driven liposomal form of prednisolone in the treatment of experimental allergic dermatitis. Pharm Chem J 2006;40:177-81.
55. Raza K, Singh B, Mahajan A, Negi P, Bhatia A, Katare O P. Design and evaluation of flexible membrane vesicles (FMVs) for enhanced topical delivery of capsaicin. J Drug Target 2010 [In Press].
56. Singh B, Mehta G, Kumar R, Bhatia A, Ahuja N, Katare O P. Design, development and optimization of nimesulide-loaded liposomal systems for topical application. Curr Drug Deliv 2005;2:143-53.
57. Kumar R, Singh B, Bakshi G, Katare O P. Development of liposomal systems of finasteride for topical applications: design, characterization, and in vitro evaluation. Pharm Dev Technol 2007;12:591-601.
58. Fresta M, Puglisi G. Corticosteroid dermal delivery with skinlipid liposomes. J Control Release 1997;44:141-51.
59. Frangos JE, Kimball AB. Clobetasol propionate emollient formulation foam in the treatment of corticosteroid-responsive dermatoses. Expert Opin Pharmacother 2008;9:2001-7.
60. Bhatia A, Kumar R, Katare O P. Tamoxifen in topical liposomes: development, characterization and in-vitro evaluation. J Pharm Pharm Sci 2004;7:252-9.
61. Bhatia A, Singh B, Bhushan S, Katare O P. Tamoxifenencapsulated vesicular systems: cytotoxicity evaluation in human epidermal keratinocyte cell line. Drug Del Ind Pharm 2010;36:350-4.
62. Elzainy AA, Gu X, Simons FE, Simons KJ. Hydroxyzine from topical phospholipid liposomal formulations: evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model. AAPS PharmSci 2003;5: E28.
63. Korbel JN, Sebok B, Kerenyi M, Mahrle G. Enhancement of the antiparakeratotic potency of calcitriol and tacalcitol in liposomal preparations in the mouse tail test. Skin Pharmacol Appl Skin Physiol 2001;14:291-5.
64. Prufer K, Jirikowski G F. Liposomal incorporation changes the effect of 1.25-dihydroxyvitamin D3 on the phospholipase C signal transduction pathway and the eicosanoid cascade on keratinocytes in vitro. Biochem Pharmacol 1996;51:247-52.
65. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009;60:643-59.
66. Koo J, Lee E, Lee CS, Lebwohl M. Psoriasis. J Am Acad Dermatol 2004;50:613-22.
67. Piacquadio D, Kligman A. The critical role of the vehicle to therapeutic efficacy and patient compliance. J Am Acad Dermatol 1998;39: S67-73.
68. Mustakallio KK. The history of dithranol and related hydroxyanthrones, their efficacy, side effects, and different regimens employed in the treatment of psoriasis. A review. Acta Derm Venereol Suppl (Stockh) 1992;172:7-9.
69. Mahrle G. Dithranol. Clin Dermatol 1997;15:723-37.
70. Prins M, Swinkels OQ, Bouwhuis S, de Gast MJ, Bouwman-Boer Y, van der Valk PG, et al. Dithranol in a cream preparation: disperse or dissolve? Skin Pharmacol Appl Skin Physiol 2000;13:273-9.
71. Gehring W, Ghyczy M, Gloor M, Scheer T, Roding J. Enhancement of the penetration of dithranol and increase of effect of dithranol on the skin by liposomes. Arzneimittelforschung 1992;42:983-5.
72. Gidwani SK, Singnurkar PS. Composition for delivery of dithranol. India: European Patent Office: 2003: p. 1-14.
73. Citations, Biotech product and process development and commercialization awards. In: DBT,. New Delhi: Government of India; 2007. p. 1-5.
74. Citations, Biotech product and process development and commercialization awards, Ministry of Science and Technology. In: DBT,. New Delhi: Government of India; 2006. p. 16-9.
75. Montes L, Method of treating psoriasis with cycloheximide. United States: United States Patent Office; 1972.
76. Comaish S. The effect of methotrexate on skin. Br J Dermatol 1969;81:551-4.
77. McCullough JL, Synder DS, Weinstein GD, Friedland A, Stein B. Factors affecting human percutaneous penetration of methotrexate and its analogues in vitro. J Invest Dermatol 1976;66:103-7.
78. Zaffaroni A. Therapeutic adhesive tape. United States: United States Patent Office; 1971.
79. Alvarez-Figueroa MJ, Delgado-Charro MB, Blanco-Mendez J. Passive and iontophoretic transdermal penetration of methotrexate. Int J Pharm 2001;212:101-7.
80. Alvarez-Figueroa MJ, Blanco-Mendez J. Transdermal delivery of methotrexate: Iontophoretic delivery from hydrogels and passive delivery from microemulsions. Int J Pharm 2001;215:57-65.
81. Patel H. Methotrexate ointment. United States: United State Patent Office; 1983.
82. Trotta M, Pattarino F, Gasco MR. Influence of counter ions on the skin permeation of methotrexate from water-oil microemulsions. Pharm Acta Helv 1996;71:135-40.
83. Misra AK, Padhi BK, Chougule M. Methotrexate-loaded solid lipid nanoparticles for topical treatment of psoriasis: formulation and clinical implications. Drug Del Tech 2004;4:8.
84. Pariser D, Bucko A, Fried R, Jarratt MT, Kempers S, Kircik L, et al. Tretinoin gel microsphere pump 0.04% plus 5% benzoyl peroxide wash for treatment of acne vulgaris: Morning/morning regimen is as effective and safe as morning/evening regimen. J Drugs Dermatol 2010;9:805-13.
85. Kikuchi K, Suetake T, Kumasaka N, Tagami H. Improvement of photoaged facial skin in middle-aged Japanese females by topical retinol (vitamin A alcohol): a vehicle-controlled, double-blind study. J Dermatolog Treat 2009;20:276-81.
86. Raizada AK, Khurana VK, Sharma V, Gupta RK. Recalcitrant psoriasis treated with tretinoin 0.05% cream. Indian J Dermatol Venereol Leprol 1996;62:338.
87. Schmidt JB, Donath P, Hannes J, Perl S, Neumayer R, Reiner A. Tretinoin-iontophoresis in atrophic acne scars. Int J Dermatol 1999;38:149-53.
88. Boyd AS, King LE Jr. Tamoxifen-induced remission of psoriasis. J Am Acad Dermatol 1999;41:887-89.
89. Ferrari VD, Jirillo A. Psoriasis and tamoxifen therapy: A case report. Tumori 1996;82:262-63.
90. Zhao K, Singh J. Mechanisms of percutaneous absorption of tamoxifen by terpenes: eugenol, D-limonene and menthone. J Control Release 1998;55:253-60. (Pubitemid 28477616)
91. Katare O P, Sinha VR, Bhatia A, Kumar R, Gupta S. Synergistic liposomal tamoxifen composition for topical application and method of preparing thereof. United Nations: WIPO; 2006.
92. O'Neill JL, Feldman SR. Vitamine D analogue-based therapies for psoriasis. Drugs Today (Barc) 2010;46:351-60.
93. Lin YK, Huang ZR, Zhuo RZ, Fang JY. Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery. Int J Nanomedicine 2010;5:117-28.
94. Remitz A, Reitamo S, Erkko P, Granlund H, Lauerma AI. Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol 1999;141:103-7.
95. Clayton TH, Harrison P V, Nicholls R, Delap M. Topical tacrolimus for facial psoriasis. Br J Dermatol 2003;149:419-20.
96. Yamamoto T, Nishioka K. Topical tacrolimus is effective for facial lesions of psoriasis. Acta Derm Venereol Suppl (Stockh) 2000;80:451.
97. Yamamoto T, Nishioka K. Topical tacrolimus: An effective therapy for facial psoriasis. Eur J Dermatol 2003;13:471-3. (Pubitemid 37305092)
98. Freeman AK, Linowski GJ, Brady C, Lind L, Vanveldhuisen P, Singer G, et al. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol 2003;48:564-8.
99. Iancu L, Shneur A, Cohen H. Trials with xanthine derivatives in systemic treatment of psoriasis. Dermatologica 1979;159:55-61.
100. Touitou E, Shaco-Ezra N, Dayan N, Jushynski M, Rafaeloff R, Azoury R. Dyphylline liposomes for delivery to the skin. J Pharm Sci 1992;81:131-4.
101. Ibbotson SH. Topical 5-aminolaevulinic acid photodynamic therapy for the treatment of skin conditions other than nonmelanoma skin cancer. Br J Dermatol 2002;146:178-88.
102. Fang Y P, Huang YB, Wu PC, Tsai YH. Topical delivery of 5-aminolevulinic acid-encapsulated ethosomes in a hyperproliferative skin animal model using the CLSM technique to evaluate the penetration behavior. Eur J Pharm Biopharm 2009;73:391-8.
103. Afifi T, de Gannes G, Huang C, Zhou Y. Topical therapies for psoriasis: Evidence-based review. Can Fam Physician 2005;51:519-25.
104. Pearce DJ, Spencer L, Hu J, Balkrishnan R, Fleischer AB Jr, Feldman SR. Class I topical corticosteroid use by psoriasis patients in an academic practice. J Dermatolog Treat 2004;15:235-38.
105. Korting HC, Zienicke H, Schafer-Korting M, Braun-Falco O. Liposome encapsulation improves efficacy of betamethasone dipropionate in atopic eczema but not in psoriasis vulgaris. Eur J Clin Pharmacol 1990;39:349-51.
106. Baroli B, Lopez-Quintela MA, Delgado-Charro MB, Fadda AM, Blanco-Mendez J. Microemulsions for topical delivery of 8-methoxsalen. J Control Release 2000;69:209-18.
107. Fang JY, Fang CL, Liu CH, Su YH. Lipid nanoparticles as vehicles for topical psoralen delivery: Solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm 2008;70:633-40.
108. Wu SX, Guo NR. Clinical observation on effect of triptolide tablet in treating patients with psoriasis vulgaris. Chin J Integr Med 2005;11:147-8.
109. Mei Z, Chen H, Weng T, Yang Y, Yang X. Solid lipid nanoparticle and microemulsion for topical delivery of triptolide. Eur J Pharm Biopharm 2003;56:189-96.
110. Chen H, Chang X, Weng T, Zhao X, Gao Z, Yang Y, et al. A study of microemulsion systems for transdermal delivery of triptolide. J Control Release 2004;98:427-36.
111. Thomson AW, Whiting PH, Simpson JG. Cyclosporine: immunology, toxicity and pharmacology in experimental animals. Agents Actions 1984;15:306-27.
112. Lawrence R. Novel topical and oral treatment for dermatitis and psoriasis. Drug Discov Today 2001;6:114-5.
113. Hewitt CW, Black KS. Overview of a 10-year experience on methods and compositions for inducing site-specific immunosuppression with topical immunosuppressants. Transplant Proc 1996;28:922-3.
114. Duncan JI, Wakeel RA, Winfield AJ, Ormerod AD, Thomson AW. Immunomodulation of psoriasis with a topical cyclosporin A formulation. Acta Derm Venereol 1993;73:84-7.
115. Guo J, Ping Q, Sun G, Jiao C. Lecithin vesicular carriers for transdermal delivery of cyclosporin A. Int J Pharm 2000;194:201-17.
116. Ugazio E, Cavalli R, Gasco MR. Incorporation of cyclosporin A in solid lipid nanoparticles (SLN). Int J Pharm 2002;241:341-4. (Pubitemid 34718035)
117. Boinpally RR, Zhou SL, Devraj G, Anne PK, Poondru S, Jasti BR. Iontophoresis of lecithin vesicles of cyclosporin A. Int J Pharm 2004;274:185-90.
118. Lopes LB, Collett JH, Bentley M V. Topical delivery of cyclosporin A: an in vitro study using monoolein as a penetration enhancer. Eur J Pharm Biopharm 2005;60:25-30.
119. Lopes LB, Lopes JL, Oliveira DC, Thomazini JA, Garcia MT, Fantini MC, et al. Liquid crystalline phases of monoolein and water for topical delivery of cyclosporin A: Characterization and study of in vitro and in vivo delivery. Eur J Pharm Biopharm 2006;63:146-55.
120. Verma DD, Fahr A. Synergistic penetration enhancement effect of ethanol and phospholipids on the topical delivery of cyclosporin A. J Control Release 2004;97:55-66.
121. Katare O P, Kumar R, Bhoop BS, Dogra S, Kaur I. A multicompartmental liposomal system for topical drug delivery. Kolkata (India): The Patent Office Journal; 2009. p. 6210.
122. Katare O P, Kumar R, Bhoop BS, Dogra S, Kaur I. Microemulsion organogel system for site-specific delivery of cyclosporine. Kolkata (India): The Patent Office Journal; 2009: p. 6211.
123. Liu H, Li S, Wang Y, Yao H, Zhang Y. Effect of vehicles and enhancers on the topical delivery of cyclosporin A. Int J Pharm 2006;311:182-6.
124. Bhatia A, Raza K, Singh B, Katare O P. Phospholipid-based formulation with improved attributes of coal tar. J Cosmet Dermatol 2009;8:282-8.